NCT06377228View on ClinicalTrials.gov

A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 13, 2025

Primary Completion Date

September 2, 2030

Study Completion Date

September 2, 2030

Conditions
Refractory Lupus NephritisRefractory Systemic Sclerosis
Interventions
BIOLOGICAL

TAK-007

TAK-007 IV infusion.

DRUG

Chemotherapy Agents

Fludarabine and cyclophosphamide IV infusion.

Trial Locations (1)

77030

University of Texas Health Science Center, Houston

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT06377228 - A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc) | Biotech Hunter | Biotech Hunter